Catalog No.
DHC98804
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG2-kappa
Clonality
Monoclonal
Target
ITGA4, CD49d, CD49 antigen-like family member D, CD49D, VLA-4 subunit alpha, Integrin alpha-IV, Integrin alpha-4, Gut homing receptor beta subunit, Integrin beta-7, ITGB7
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P13612 & P26010
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
AMG 181, MEDI-7183, CAS: 1342290-43-0
Clone ID
Abrilumab
Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More, PMID: 32570252
Anti-integrin therapy for inflammatory bowel disease, PMID: 29740202
Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis, PMID: 30472236
Efficacy and safety of abrilumab, an α4β7 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study, PMID: 30739435
Emerging Therapies for Inflammatory Bowel Disease, PMID: 30374806
Interfering with leukocyte trafficking in Crohn's disease, PMID: 31327399
Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease, PMID: 29767705
Anti-integrin drugs in clinical trials for inflammatory bowel disease (IBD): Insights into promising agents, PMID: 34449288
Clinical pharmacology of AMG 181, a gut-specific human anti-α4β7 monoclonal antibody, for treating inflammatory bowel diseases, PMID: 24803302
Pharmacology of AMG 181, a human anti-α4 β7 antibody that specifically alters trafficking of gut-homing T cells, PMID: 23425116
Gut-directed therapeutics in inflammatory bowel disease., PMID:40305008
[Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti Integrins]., PMID:39176460
Increased stable integration efficiency in CHO cells through enhanced nuclear localization of Bxb1 serine integrase., PMID:38926833
Drug-Induced Progressive Multifocal Leukoencephalopathy (PML): A Systematic Review and Meta-Analysis., PMID:38321317
Anti-Integrins for the Treatment of Inflammatory Bowel Disease: Current Evidence and Perspectives., PMID:34466013
Anti-integrin drugs in clinical trials for inflammatory bowel disease (IBD): insights into promising agents., PMID:34449288
Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More., PMID:32570252
Interfering with leukocyte trafficking in Crohn's disease., PMID:31327399
Efficacy and safety of abrilumab, an α4β7 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study., PMID:30739435
Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis., PMID:30472236
Emerging Therapies for Inflammatory Bowel Disease., PMID:30374806
Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease., PMID:29767705
Anti-integrin therapy for inflammatory bowel disease., PMID:29740202
Clinical pharmacology of AMG 181, a gut-specific human anti-α4β7 monoclonal antibody, for treating inflammatory bowel diseases., PMID:24803302
Pharmacology of AMG 181, a human anti-α4 β7 antibody that specifically alters trafficking of gut-homing T cells., PMID:23425116
For research use only. Not for human or drug use.
